Orthogonal comparison with established Simoa assays
NULISAseq and Simoa measurements were strongly correlated for NfL and GFAP, providing direct cross-platform evidence for those two analytes.
↳ Results, Fig. 3A–B
Motor neuron disease (MND) presents with phenotypic heterogeneity, is diagnostically challenging, and has poor prognosis. The absence of accessible blood-based biomarkers has hampered progress towards precision medicine. Highly sensitive immunoassays offer considerable promise for identifying blood-based biomarkers informing underlying pathophysiology and enabling accurate diagnosis and monitoring. We report findings on parallel use of the ultra-sensitive multiplexed NUcleic Acid-Linked Immuno-Sandwich Assay (NULISA) and single molecule array (Simoa), to interrogate serum from people with MND. Sera (48 MND, 38 controls) were analysed using a NULISAseq targeted neurodegenerative panel and a Simoa neurofilament light chain (NfL) and glial fibrillary acid protein (GFAP) duplex assay. Neurofilament light and heavy chain, total tau (t-tau), phosphorylated tau (pTau)-181, pTau-217, pTau-231, fatty acid binding protein 3, amyloid beta (Aβ) 38 and Aβ40 levels were significantly elevated in MND (P < 0.05). Simoa and NULISAseq assays demonstrated strong correlations for NfL and GFAP (r > 0.90). Use of the multiplexed NULISAseq panel confirmed a well-established NfL elevation in MND, and replicated findings for other proteins from recent studies. Results add confidence in the validity and reproducibility of biomarkers identified using NULISAseq, while offering insights into the underlying pathophysiology and heterogeneity of MND.
Neurofilament light and heavy chain, total tau (t-tau), phosphorylated tau (pTau)-181, pTau-217, pTau-231, fatty acid binding protein 3, amyloid beta (Aβ) 38 and Aβ40 levels were significantly elevated in MND (P < 0.05).
cross-sectional unadjusted comparisons limit disease specificity, especially for low-detectability pTau-217
Simoa and NULISAseq assays demonstrated strong correlations for NfL and GFAP (r > 0.90).
reported Spearman correlations directly support the claim for both measured analytes
Results add confidence in the validity and reproducibility of biomarkers identified using NULISAseq.
two-analyte cross-platform correlation cannot establish broader biomarker validity or reproducibility
Derived from the full evaluation — not a separate score.
Strengths
NULISAseq and Simoa measurements were strongly correlated for NfL and GFAP, providing direct cross-platform evidence for those two analytes.
↳ Results, Fig. 3A–B
The workflow reports a randomized plate map, internal-control acceptance ranges, detectability thresholds, duplicate Simoa measurements, and a CV criterion.
↳ Methods, NULISAseq Profiling and Simoa sections
The discussion compares the serum findings with recent plasma and genetic-ALS NULISAseq studies and delineates the serum and broader-MND extensions.
↳ Discussion, paragraphs 2–4
Limitations
Age and sex differed between disease and control groups, but biomarker comparisons used unadjusted independent t-tests without matching, regression, stratification, or sensitivity analysis.
↳ Methods, Statistical Analysis; Results, paragraphs 1–2; Discussion, limitations paragraph
Clustering and ROC analyses were conducted in the discovery sample using the nine proteins selected as significant, without cross-validation or independent validation. This limits claims of clear separation, heterogeneity, and diagnostic performance.
↳ Results, Fig. 2B and Supplementary Fig. 9; Discussion, heatmap-analysis paragraph
The Conclusion invokes astrocytic degeneration, pathophysiological insight, and assay robustness although GFAP was unchanged and the study was a small, unadjusted cross-sectional pilot.
↳ Discussion, neuroinflammation and limitations paragraphs; Conclusion
The serum panel identified nine FDR-significant proteins and reproduced the established NfL signal, while Fig. 3 provides direct cross-platform correlation evidence for NfL and GFAP. Methodological credit is limited by unadjusted t-tests despite documented age and sex differences between groups. The selected-feature clustering and in-sample ROC analysis do not independently establish diagnostic separation or MND heterogeneity. The paper is therefore best interpreted as an exploratory replication and assay-concordance study rather than clinical validation of a disease-specific panel.
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
The study adds an incremental serum-based replication across a mixed MND cohort and a two-analyte comparison with Simoa. Its advance remains limited because NfL elevation is established and several panel findings overlap recent NULISAseq studies.
Use of the multiplexed NULISAseq panel confirmed a well-established NfL elevation in MND
Randomized plate allocation, assay QC, FDR correction, and duplicate Simoa measurements support the laboratory workflow. The primary comparisons remain unadjusted for documented age and sex differences, while control selection and in-sample feature evaluation add uncertainty.
These exclusions affected the sex distribution difference between groups for the final analysis
The manuscript follows a clear progression from hypotheses through multiplex testing and cross-platform comparison. Central claims about assay robustness, astrocytic degeneration, and heterogeneity are stronger than the unadjusted pilot and selected-feature clustering support.
provide further confidence in the validity and robustness of the NULISAseq assay
The discussion compares the findings with recent NULISAseq and broader biomarker studies and identifies the serum and mixed-MND extensions. Age and sex imbalance is acknowledged but not traced through the certainty of disease-specific biomarker interpretations.
differences between the age and sex of disease and control groups
Caveats4 of 4 checks
One reported value does not reconcile, but the key claims do not rest on it.
No reporting or research-conduct concern was raised that warrants a grounded finding.
Ethics approval: declared · Preregistration: not stated · Data availability: declared · Code availability: declared
33 references in manuscript 33 of 33 checkable references found in an index
References not verified automatically are resolved manually within 24 hours.
No retraction or expression of concern found in Crossref (includes Retraction Watch).
Sources: Crossref (incl. Retraction Watch) ✓
The primary claim rests on a single cross-sectional observational pilot cohort of 48 MND cases and 38 controls with no independent replication or validation of the biomarker elevations.
“pTau may therefore be a helpful biomarker reflecting distinct pathology, and of utility for disease monitoring including in clinical trials.”
The paper names possible real-world uses of the biomarker findings, diagnosis and disease monitoring, but does not specify who would act on them or in what concrete decision setting.
Neurologists and clinical trial teams could adopt validated blood-based biomarkers such as NfL and pTau to support MND diagnosis, subtyping and disease monitoring.
The modest single-cohort cross-sectional design requires replication in larger, well-characterized longitudinal cohorts before these biomarkers can enter clinical use.
Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3
AI-generated, human-governed. Something look off? Contact us to request a review.
Keep reading
Other papers Nabu has evaluated blind, starting with the same field.
Selvaraj, Livesey, Zhao, et al. · 2018 · Basic medicine
increased expression of GluA1 AMPA receptor (AMPAR) subunit occurs in MNs with C9ORF72 mutations that leads to increased Ca2+-permeable AMPAR expression and results in enhanced selective MN vulnerability to excitotoxicity.
TentativeStavrou, Heffernan, Carter, et al. · 2026 · Basic medicine
human-induced pluripotent stem-cell-derived astrocytes carrying the C9ORF72 mutation disrupt mitochondrial axonal transport and mitochondrial function in cocultured motor neurons (MNs)
SupportedKasper, Lehto, Jürs, et al. · 2026 · Clinical medicine
CSF p-tau and total-tau levels were strongly associated with domain-specific cognitive performance.
Tentative